MT-401-OTS not checked

Marker Therapeutics, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“MT-401-OTS is an off the shelf cellular therapy product given by IV infusion through either a peripheral or central line.”In the company’s words, NCT06552416 on ClinicalTrials.gov
Tested for
Acute Myeloid Leukemia, in Relapse, MDS
Main trialPhase 1
“This study is a Phase 1 multicenter, open-label study evaluating the safety and efficacy of escalating doses of MT-401-OTS in 2 participant populations: 1) Those with intermediate or high-risk AML per 2022 ELN criteria who have evidence of MRD and/or \</= 10% blast following prior induction therapy or at least 4 cycles of nonintensive therapy and 2) those with high- or very-high-risk MDS per 2023 IWG criteria and who have residual disease with \</= 10% blasts following treatment with an HMA-based therapy.”In the company’s words, NCT06552416 on ClinicalTrials.gov

Other drugs for Acute Myeloid Leukemia, in Relapse

All 140 drugs for Acute Myeloid Leukemia, in Relapse

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Recruiting Sep 2029 Safety of MT-401-OTS in Patients With Relapsed AML or MDS
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow MT-401-OTS

Following is part of Solo: you see every change to MT-401-OTS the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in